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Introduction
A radically new approach to cancer therapy will become 
possible when cytotoxic agents will be selectively directed to the 
renewing cancer stem cells (CSCs). In other words, the new goal 
of therapeutic research should be to exploit crucial metabolic 
peculiarities in the potentially vulnerable targets of CSCs, not 
expressed by differentiated tissues. Little is known as yet about 
the metabolism of CSCs, but agreement has been reached in the 
characterization of some of their features, which gives grounds 
for hope that the new approach described below may prove to be 
effective.1
Anaplastic tumors are constantly developing successful 
strategies to survive in hypoxia, this being an exclusive prerogative 
essential for maintaining their stemness.2 The prerogative is 
coupled to a biochemical marker that was discovered by Warburg 
as long ago as 1925, opening the way to explore cancer cell 
metabolism. This marker is the obligatory conversion of glucose 
into lactate in air, what Warburg called “aerobic glycolysis”; it is 
shared by embryonic tissues, but is generally absent in normal 
differentiated cells, which produce lactate only in anaerobiosis, a 
process referred to as “anaerobic glycolysis”.3 The explanation of 
this fundamental distinction has been the object of innumerable 
studies and debates, but still remains unsolved.
We approached this problem by arguing that aerobic 
glycolysis must imply some selective advantage for cancer cells 
and for embryonic cells adapted to hypoxia, when first exposed 
to oxygen. In fact, hypoxia adaptation requires a biochemical 
trim characterized by a glycolytic-oriented metabolism that 
counterbalances a poor mitochondrial apparatus.4 We have 
previously shown that the transition from this status to that 
of growth and differentiation requires some O
2
-dependent 
evolutionary steps, which lead to the amplification of the 
mitochondrial apparatus and the related metabolic network.2,5,6 
In these primitive steps, O
2
 must be utilized through the 
respiratory chain to set the cellular redox state, expressed by the 
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We have previously shown that peculiar metabolic features of cell adaptation and survival in hypoxia imply 
growth restriction points that are typical of embryonic stem cells and disappear with differentiation. Here we provide 
evidence that such restrictions can be exploited as specific antiblastic targets by physiological factors such as pyruvate, 
tetrahydrofolate, and glutamine. these metabolites act as powerful cytotoxic agents on cancer stem cells (CSCs) when 
supplied at doses that perturb the biochemical network, sustaining the resumption of aerobic growth after the hypoxic 
dormant state. experiments were performed in vivo and in vitro using CSCs obtained from various anaplastic tumors: 
human melanoma, leukemia, and rat hepatoma cells. pretreatment of melanoma CSCs with pyruvate significantly reduces 
their self-renewal in vitro and tumorigenicity in vivo. the metabolic network underlying the cytotoxic effect of the 
physiological factors was thoroughly defined, principally using AH130 hepatoma, a tumor spontaneously reprogrammed 
to the embryonic stem stage. this network, based on a tight integration of aerobic glycolysis, cellular redox state, and 
folate metabolism, is centered on the cellular NADp/NADpH ratio that controls the redox pathway of folate utilization in 
purine synthesis. on the whole, this study indicates that pyruvate, FH4, and glutamine display anticancer activity, because 
CSCs are committed to survive and maintain their stemness in hypoxia. When CSC need to differentiate and proliferate, 
they shift from anaerobic to aerobic status, and the few mitochondria available makes them susceptible to the injury of 
the above physiological factors. this vulnerability might be exploited for novel therapeutic treatments.
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NADP/NADPH ratio, at values permitting crucial steps of folate 
utilization in the synthesis of purine ring. This synthesis is, in 
turn, an essential preliminary condition for the G
1
/S transition 
of the cell cycle.5,6 Then, in order to exit from the quiescent state, 
stem cells must utilize O
2
 through the mitochondrial respiratory 
chain. In cells endowed with few mitochondria, like the hypoxia-
adapted cells, this step must be protected from the saturation of 
the respiratory chain by pyruvate deriving from active glycolysis, 
necessary for ATP generation; otherwise, pyruvate itself becomes 
a potent cytotoxic agent and must be somehow eliminated 
before entering the Krebs cycle. Consistently, pyruvate addition 
to cancer stem cells produces a strong inhibition of transition 
from the anaerobic quiescent state to aerobic stimulation. In 
other words, the hypoxia-adapted metabolism implies a strong 
vulnerability to a classical physiological substrate, such as 
pyruvate. This observation led us to devise a series of studies 
aimed at exploring the biochemical background of this paradox, 
seeking to demonstrate the crucial role of the cellular redox state 
(NADP/NADPH ratio) in this event. The above metabolic 
trim, which characterizes cancer cells, turned out to be typical 
of embryonic stem cells (ESCs), which come into being in the 
blastula and then spread within the differentiated tissues to 
become adult stem cells, supporting the renewal of these tissues.7 
Such a metabolic configuration persists in the embryonic tissues 
and disappears with differentiation, but is restored in tumors 
generated in adult populations.
It seemed to us that further research in this field might reveal 
metabolic circuits that are preserved in cancer stem cells and 
could be the target of a radical antitumor therapy. At the present 
moment, however, we have obtained solid information about this 
target, showing that it represents a complex metabolic network 
susceptible to inhibition by physiological compounds, such as 
classical substrates of the Krebs cycle, pyruvate and glutamine, 
and the vitamin FH
4
. The present study demonstrates, for the 
first time, the central role of the cellular redox NADP/NADPH 
ratio in mitotic cycle regulation in cancer stem cells.
Figure 1. the role of cellular redox-state in the cytotoxic activity of physiological agents: the involvement of purine and folate metabolism. (A) the 
sensitivity of various cancer and normal stem cell populations to the cytotoxic activity of pyruvate. Values are expressed as IC50 of cell growth in the 
presence of varying concentrations of the substrate. (B) the inhibition of cell recruitment into S of AH130 cells by the Krebs cycle substrates as a func-
tion of the corresponding rate of oxygen consumption. oxygen consumption (ΔQo2) is expressed as μl of o2 per mg of dry weight per hour. Ketog, 
α-ketoglutarate; Succ, Succinate; Mal, Malate; Fum, Fumarate; Citr, Citrate; oxalAc, oxalacetate; pyr, pyruvate. All substrates are used at [10 mM]. R = rate 
of 14C-thymidine incorporation into DNA per 90min per 106 viable cells at t = 18 h of incubation in air. Values are expressed as % of control. (C) effects of 
purine and pyrimidines on pyruvate inhibition of AH130 cell recruitment into S. Additions: pyr = 10 mM pyruvate; ade, adenine; guan, guanine; thym, 
thymidine; cyt, cytosine; urac, uracile. All bases are used at [0.5 mM]. All additions were performed at time 0. Values are means ± SeM of 3 experiments. 
(D) the antimycin An inhibition of adenine pool and its removal by folate in AH130 cells. Values are expressed as nmol/5 × 107 viable cells at t = 18 h of 
incubation in air and are means ± SeM of 6 experiments. Ant A (6 × 10−6M), F (100 μmol) were added at t = 0. ant A, antimycin A; F, folate. (E) the antimy-
cin A inhibition of guanine pool and its removal by folate in AH130 cells. Values are expressed as nmol/5 × 107 viable cells at t = 18h of incubation in air 
and are means ± SeM of 3 experiments. Ant A and F were added at t = 0. (F) the effects of various treatments on the intracellular NADp/NADpH ratio in 
AH130 cells. NADp and NADpH were estimated by HpLC technique as reported in “Materials and Methods” and are expressed as percentage of control at 
t = 18 h of incubation in air, and are means ± SeM of five experiments. gln, glutamine (5 mM). **P < 0.02; ***P < 0.001.
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Results
A preliminary screening performed on cell populations of 
varying histogenesis and tumorigenicity displayed a higher 
sensitivity to pyruvate in cancer cell lines as compared with 
normal cell populations (Fig. 1A). To be more precise, the IC
50
 
was 7.5 mM for the highly anaplastic hepatoma ascites AH130, 
and about 10 mM for the 3 human melanoma lines, A375, M26c, 
and SSM2c. A similar sensitivity was displayed by the K562 line, 
composed of undifferentiated blast cells.8,9 By contrast, 2 normal 
stem populations, namely, bone marrow hematopoietic cells 
(BMC) and lymphocytes, proved to be much less sensitive. Taken 
as a whole, these data indicate that pyruvate sensitivity reflects a 
metabolic trim, which, without being limited to cancer cells, is 
greatly intensified in aggressive malignancies.
The AH130 hepatoma model
The AH130 tumor closely mirrors the cancer profile at 
embryonic stages of de-differentiation and hypoxia adaptation.2,6 
It was generated in liver by the carcinogen o-aminoazotoluene, 
which bound to and abolished the p53 protein, producing a 
Figure 2. the central role of the NADp/NADpH ratio in the control of ascites cell recruitment into S. the paradoxical effect of FH4 and its similarity to that 
of MtX. (A) the opposite effect of F and FH4 on the NADp/NADpH ratio. the ratio was determined at 18 h of incubation in air. Additions were performed 
at t = 0. F and FH4 = 100 μM. (B) the effect of F and FH4 on the NADp or NADpH intracellular concentration. Note that in the presence of folate, NADp 
concentration is much higher that of NADpH, while FH4 inverts this ratio. Values are expressed as nmol/5 × 10
7 viable cells at t = 18 h of incubation in 
air. (C) the effects of F, FH4, MtX (10
−6 M) and gln on the NADpH intracellular concentration. Values are expressed as nmol/5 × 107 viable cells at t = 18 h 
of incubation in air and are means ± SeM of 3 experiments. (D) the effects of FH4, MtX and gln on AH130 cell recruitment into S (R). Values are means 
± SeM of 3 experiments. (E) the correlation between AH130 cell recruitment into S and the NADp/NADpH under various conditions. Correlation index, 
R = 0.98. *P < 0.05; **P < 0.02; ***P < 0.001.
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genomic instability that promoted both an intense neoplastic 
progression and a significant reprogramming to embryonic 
staminality. This reprogramming was demonstrated by the 
expression of embryonic transcription factors (ETFs), such as 
Nanog, Klf4, and c-Myc, in the entire cell population.2 When 
injected into peritoneal cavity of a new host rat, this stem 
population grows with an unlimited capacity for self-renewal for 
as long as oxygen is available. At more advanced stages, when 
the intraperitoneal pO
2
 falls to ~0, almost 100% of the cells 




; when transferred into aerobic culture, 
the entire population is synchronously recruited into S.2 Overall, 
this population proved to be a unique source of reprogrammed 
cancer stem cells obtainable in such a quantity (billions) 
naturally synchronized by hypoxia and synchronously recruited 
into S upon exposure to normoxia. In this model we were able to 
demonstrate that the G
1
/S transition is abolished by antimycin A, 
a powerful inhibitor of the electron transport to oxygen through 
the mitochondrial respiratory chain,6,10 and it was also possible 
to bring about a detailed quantitative study of the role of aerobic 
glycolysis in prevention of the cell cycle inhibition by pyruvate. 
We also showed that varying levels of inhibition were obtained 
with the addition of classical substrates of the Krebs cycle, first 
and foremost pyruvate, this being the initial observation that led 
to the research reported in this paper.
The inhibitory activity of the Krebs cycle substrates is a 
function of their oxidation rate through the respiratory chain
In Figure 1B, cell recruitment into S, measured by the 
rate of incorporation of 14C-thymidine into DNA at 18 h of 
incubation in air (R), is reported as a function of the oxygen 
consumption (ΔQO
2
)11 produced by the respective substrates. 
As shown, this recruitment is inhibited as a strict function of 
ΔQO
2
, which suggests that the oxidation of substrates governs 
growth inhibition, so that at 10 mM, pyruvate produced the 
same level (80%) of inhibition as antimycin A.5,6 This paradox 
suggested that an excess of oxidizable substrates saturates the 
respiratory chain, at the expense of some redox step, limiting 
the activation of the cell cycle.2,6 As demonstrated below, this 
step was individuated in a redox reaction of a complex metabolic 
network responsible for the synthesis of the purine ring.
The regulation of purine pools by the cellular redox state: 
The role of the NADP/NADPH ratio and its dependence on 
folate
The central role of a cellular redox pathway in purine 
synthesis was demonstrated by the following results: (1) Pyruvate 
inhibition of cell recruitment was totally removed by the addition 
of 0.5 mM adenine and reduced by half adding guanine, while 
pyrimidines (thymine, cytosine, uracil) were ineffective (Fig. 1C). 
(2) Antimycin A produced a 70% reduction of the intracellular 
adenine and guanine pools, measured by HPLC analysis at 18 h 
of incubation in air (Fig. 1D and E): these results demonstrate 
that the synthesis of these bases requires a respiration-dependent 
oxidative step. (3) The addition of folate removed antimycin 
A inhibition of adenine and guanine pools: this leads us to 
ascribe the redox limiting step of folate utilization in purine 
synthesis to the NADP/NADPH ratio, which governs the 
generation of the essential precursor methenyl-tetrahydrofolate 
(CH-FH
4










(Fig. 6). (4) The mitochondrial respiratory chain gears the 
cellular NADP/NAPH ratio: this was made evident by the 
experiments reported in Figure 1F, showing that antimycin 
A, as well as pyruvate, produces a 90% fall of this ratio. Such 
inhibition is totally removed by folate, which doubles the NADP/
NAPH ratio of the control.
The tumor inhibition by tetrahydrofolate (FH
4
)
Another unpredictable feature of cancer stem cells emerged 
from the data reported in Figure 2, showing that the addition 
of folate and FH
4
 has opposite effects on the NADP/NADPH 
ratio, which was strongly enhanced by folate and drastically 
diminished by FH
4
 (Fig. 2A). It is important to note that this 
diminution was accounted for by the NADPH increase at the 
expense of folate (Fig. 2B). These effects of FH
4
 closely mimic 
those of Metatrexate, the powerful inhibitor of the DHFR, 
producing: (1) a comparable increase of the cellular NADPH 
levels (Fig. 2C); and (2) the inhibition of cell recruitment into 
S, as measured by the thymidine incorporation rate into DNA 
(Fig. 2D). Keeping in mind that FH
4
 is the biologically active 
derivative of folates, taken in their totality, these results configure 
another apparent paradox emerging from this study.
The tumor inhibition by glutamine
It has been recently demonstrated that glutamine, an 
essential factor in culture media,12 contributes to the generation 
of NADPH necessary to the reductive syntheses through the 
glutaminolytic pathway.13,14 However, the data reported above 
demonstrate that the increment of NADPH inhibits cancer stem 
cell recruitment into S. As shown in Figure 1F, the addition of 
5 mM glutamine consistently brought about a decrease in the 
NADP/NADPH ratio similar to that produced by antimycin A 
and pyruvate, due to the increase in NADPH (Fig. 2C). This 
reduction is accompanied by 50% inhibition of cell recruitment 
(Fig. 2D). These results reveal another paradoxical response of 
cancer stem cells to physiological agents, in keeping with the 
crucial role of the NADP/NADPH ratio in cell cycle activation.
The central role of the NADP/NADPH ratio in cancer cell 
cycle activation
On the evidence of the data summarized in Figure 2E, the 
NADP/NADPH ratio appears to be the key growth regulator 
of cancers of different histogenesis, whatever the factor added 
in culture, including antimycin A, pyruvate, and folate, and 
whatever the source of NADPH, including glutamine, through 
the glutaminolytic pathway.13,14
The melanoma model
We employed the human melanoma cell line A375 and 2 
metastatic melanomas obtained from patients (SSM2c and 
M26c), using a protocol15 suitable to estimate the effects of 
physiological cytotoxic agents or MTX on self-renewal of 
these cell populations. These cells were transferred into flasks 
containing a medium supporting primary spheres generation 
from single cells. Sphere formation is considered a selection 
method that enriches for cancer stem cells. These spheres were 
dissociated and treated with various agents for 5 days up to the 
formation of secondary spheres, as illustrated in Figure 3A–E 
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(A375), Figure 3F–J (SSM2c), and Figure 3K–O (M26c). Folate 
treatment of A375 cells (Fig. 3B) did not cause any significant 
effect on the sphere production; on the contrary FH
4
 and 
pyruvate (Fig. 3C and D) practically abolished sphere formation 
to the same extent of MTX (Fig. 3E). The abolition of spheres 
was accompanied by extensive apoptotic cell loss, as shown in 
Fig. 3P and Q by the strong positivity to cleaved caspase 3. 
Similar results were obtained for the 2 metastatic melanomas, 
SSM2c and M26c (Fig. 3F–J and K–O, respectively). These data 
indicate that the physiological agents FH
4
 and pyruvate exert 
a strong cytotoxic effect on melanoma cells, similar to that of 
MTX, drastically interfering with sphere formation. The effects 
of these compounds on cell number in culture are shown in 
Figure 4A, which reports the total number of cells obtained by 
the dissociation of secondary spheres at the end of treatment. 
This number was strongly reduced by each treatment in all 3 
lines, with a minor sensitivity in SSM2c to FH
4
 200 μM and 
some degree of resistance to MTX by the A375 cells. Overall, the 
highest level of sensitivity displayed by the 3 lines was that to the 
treatment with pyruvate.
Crucial information was obtained in these experiments by 
measuring the self-renewal of cells dissociated from secondary 
spheres. To this purpose, these cells were plated at limiting 
dilution (1 cell/μl) up to spheres formation (tertiary spheres) 
in the absence of any treatment. The number of these spheres 
is reported in Figure 4B–D. As shown, folate was ineffective, 
whereas pyruvate, FH
4
, and MTX strongly reduced the 
production of tertiary spheres. A comparison among the 3 lines 
indicates that the response is substantially similar, except for the 
striking sensitivity of A375 cells to 200 μM FH
4
. These results 
indicate that the cytotoxicity of the tested physiological agents 
not only reduces the melanoma cell generation, but it is also 
Figure 3. the cytotoxic effects of physiological agents on melanoma stem cells. (A–O) effects of various treatments on sphere formation from A375 
(A–E), SSM2c (F–J), and M26c cells (K–O). f = 100 μM, FH4 = 100 μM, pyr = 20 mM, MtX = 10
−6M. (P) the apoptotic death of A375 melanoma cells induced 
by FH4 treatment, as revealed by anti-cleaved caspase3 antibody immunostaining. Note the fragmented apoptotic nucleus (Hoechst) and the intense 
expression of the caspase in the cytoplasm after FH4 treatment. Scale bar = 100 μm. (Q) percentage of Cleav caspase 3-positive cells after treatment with 
cytotoxic physiological agents.
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memorized, influencing the self-renewal ability by the further 
sphere generation after the agent removal. This conclusion is 
most relevant for the interpretation of the action mechanism 
of the cytotoxicity. This mechanism cannot be attributed now 
exclusively to a direct metabolic effect, but it is also brought 
about through a memorization influence (see “Discussion”). 
This “memorization process” was confirmed by the in vivo 
experiments reported below.
In vitro treatment with pyruvate reduces tumorigenicity of 
melanoma cancer stem cells: The cytotoxic nature of pyruvate
The memorization was confirmed by the in vivo experiments 
reported in Figure 5. An aliquot of A375 dissociated cells 
from primary spheres was split in 2 cultures, which were 
incubated for 1 wk either in presence of 20 mM pyruvate or 
PBS. At the end of this incubation, 103 viable pyruvate- or 
PBS-treated cells were injected subcutaneously into nude mice 
to test their tumorigenicity. As shown in Figure 5A, pyruvate 
pretreatment caused an inhibition of tumor growth, determining 
a remarkable reduction of tumor number and size (Fig. 5B). 
Histological examination of xenograft cross sections showed 
that the central parts of tumors derived from both PBS-treated 
and pyruvate-treated CSC were necrotic, consistent with the 
progressive pO
2
 decrease from the periphery to the center of 
the tumor. The periphery of tumors derived from PBS-treated 
melanoma cancer stem cells (Fig. 5C, upper pictures) is thicker 
and more preserved than that of pyruvate-treated melanoma CSC 
(Fig. 5D, lower pictures); moreover, in the latter, cells appear 
visibly necrotic. This implies that, unlike the apoptotic effect 
of pyruvate pretreatment on melanoma cells in vitro (Fig. 3P), 
the necrotic effect produced in vivo was evidently brought about 
without exploiting the ATP-dependent apoptotic program of 
cell death. It is conceivable that the hypoxic environment of the 
tumor in vivo is responsible for this reinforced cytotoxicity of 
pyruvate.
Discussion
This study demonstrates that the metabolic configuration 
peculiar to cancer stem cells is responsible for both the successful 
strategy of neoplastic development in order to ensure survival 
in hostile environments, and the reason for its vulnerability to 
crucial physiological agents.
Figure 4. the inhibition of self-renewal by various agents in melanoma stem cells. (A) the effects of treatments with various agents on the number of 
cell dissociated from secondary spheres in the 3 melanoma cell lines. (B–D) the effects of treatments on self-renewal in A375, SSM2c, and M26c cells. 
Bars represent the number of spheres generated in the absence of treatments by dissociated cells obtained from the secondary spheres. Values are 
means ± SeM of 3 experiments. *P < 0.05; **P < 0.02; ***P < 0.001.
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The anticancer cytotoxicity displayed by pyruvate, FH
4
, and 
glutamine derives from the metabolic organization specific to 
stem cells committed to survive and maintain their stemness in 
hypoxia. This organization is constantly configured in highly 
anaplastic tumor cells, revealing unsuspected vulnerabilities of 
cancer. As summarized in the diagram in Figure 6, despite their 
different chemical structure and metabolic role, the 3 substances 
produced remarkably similar effects by means of a remarkably 
similar mechanism of a kind that could not have been predicted. 
What happens is that all 3 are similarly targeted to the metabolic 
checkpoint, which regulates the activation of the stem-cell cycle 
at the G
1
/S transition. The following detailed definition of the 
metabolic sequence altering this checkpoint was allowed in the 
AH130 model, showing that the final target of the cytotoxic 
agents on embryonic cancer cells is the redox NADP/NADPH 
ratio. This ratio governs folate utilization in the amplification 
of purine pools, which is necessary to start DNA neosynthesis 
in hypoxia-starved stem cells (Fig. 6A). The crucial step in 











DH.14 Consequently, any 
reductive shift of the NADP/NADPH ratio tends to impair cell 
recruitment into S. The addition of pyruvate, as well as FH
4
 and 
glutamine, produces a drastic shift of the ratio, accounting for a 
proportional inhibition of the recruitment.
Pyruvate decreases the NADP/NADPH ratio by saturating the 
respiratory chain and, thus, mimics the blockade by antimycin A. 
Such interpretation is confirmed by the removal of this blockade 
by folate, which abolishes this decrease (Figs. 1 and 2).This fact 
rules out that the cytotoxicity of pyruvate might be mediated by 
some defect of the activity of pyruvate dehydrogenase (PDH) 
Figure 5. pre-treatment of A375 melanoma cells with pyruvate in vitro reduces tumor growth in vivo. (A) the inhibitory effect of pyruvate pre-treatment 
on melanoma growth in vivo. A375 melanoma spheres were treated and injected in athymic mice as reported in “Materials and Methods”, and tumor devel-
opment followed up to 32 d from injection. Scale bar = 10 mm. (B) Quantification of tumor volume. Values represent the averages of tumors developed 
at various times and expressed as mean ± SeM (n = 12, each). (C) Histological sections of tumors derived from pBS- (upper pictures) and pyruvate-treated 
melanoma stem cells (lower pictures) counterstained with Hematoxylin and eosin (H&e). Scale bar right pictures = 100 μm, left pictures = 500 μm.
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as well as that of the regulatory phosphatase and kinase. This 
is an important point with regard to our interpretation, in 
view of the fact that PDH, a gatekeeper linking glycolysis to 
oxidative metabolism, acts a potent barrier against malignant 
transformation (Kaplon et al., 2013).16 Both blockade and 
saturation impair the shuttle mechanisms, which transport the 
reducing equivalents generated by the cytosolic dehydrogenases 
into mitochondria, to be disposed of by the respiratory chain 
(Fig. 6C).17
The cytotoxicity of FH
4
 is mediated by the restriction of the 
reaction F + NADPH® FH
4 
+ NADP. This restriction should 
account for the reductive shift of the NADP/NADPH ratio, 
demonstrated by our experiments, down to values incompatible 
with the purine pool amplification. All in all, an excess of 
FH
4
 behaves like an inhibitor of DHFR; this interpretation is 
supported by the demonstration that a powerful inhibitor of this 
enzyme, MTX, produces the same increment of cellular NADPH 
as that brought about by FH
4
, together with a similar inhibition 
of cell recruitment into S (Fig. 2).
The central role of the NADP/NADPH ratio in the 
pathogenesis of the cytotoxicity of physiological agents is 
further confirmed by the inhibitory effect of glutamine, whose 
addition determines a reductive shift of the ratio through the 
glutaminolytic pathway.12,13
To summarize thus far: the common target of the cytotoxic 
activity of physiological agents is purine neosynthesis, through 
the alteration of the cellular redox state expressed by the cytosolic 
NADP/NADPH ratio (Fig. 6).
An alternative mechanism underlying the necrotic or apoptotic 
cytotoxicity of the agents examined in this study is the persistence 
of this activity in vitro and in vivo long after this substrate has 
been removed or exhausted (Figs. 3–5). This long-term effect, 
shared by pyruvate, FH
4
, and MTX, is traceable to a fixable, 
epigenetic influence on ETFs, proved to regulate the activation 
Figure 6. the metabolic network which regulates the cell cycle activation at the o2-dependent G1/S transition. the core of the network is the cellular 
redox-state expressed by the cytosolic NADp/NADpH ratio. this ratio (A) regulates the transfer of reducing equivalents (H) from the methylentetrahy-
drofolate (CH2-FH4) to methenyltrahydrofolate (CH-FH4), a crucial NADp-dependent reaction generating NADpH. this is a limiting step of the synthesis 
of purine ring (B), required for the amplification of purine pools indispensable for the G1–S transition. A fundamental role in the regulation of the NADp/
NADpH ratio is played by folate, whose reduction to FH4 by the dehydrofolic reductase (DHFR) generates NADp (A). the addition of an excess of the reac-
tion product, FH4, can impair the DHFR activity, leading to an increment of NADpH, with the consequent reductive shift of the NADp/NADpH ratio and 
the inhibition of the G1/S transition. Consistently, FH4 mimics the effects of MtX, a powerful inhibitor of DHFR (A), incrementing the NADpH levels and 
inhibiting cell recruitment into S. Whatever the mechanism incrementing the cytosolic NADpH, including an excess of glutamine through the glutami-
nolytic pathway (A), has an inhibitory effect, unless it is removed by the shuttle mechanisms, which discharge the cytosolic reducing equivalents onto 
the mitochondrial respiratory chain. this role of the shuttles accounts for the fact that the activity of the chain is crucial for the G1/S transition, which is 
impaired by a specific inhibitor like antimycin A (C). A similar inhibition can be performed whenever the chain, although not inhibited, it is saturated by 
reducing equivalents produced by oxidizable substrates of the Krebs cycle, mostly pyruvate.
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of the stem-cell cycle. Actually, we demonstrated that pyruvate 
modifies the assembly of the complex transcriptional loop of 
Nanog, Klf4, and c-Myc, which governs the pO
2
-dependent cycle 
activation of ascites hepatoma stem cells that we described in our 
previous work.2 In this loop, Nanog and Klf4 antithetically control 
the expression of c-Myc and, hence, the activation of the cell cycle. 
The addition of pyruvate shifted the Nanog/Klf4 ratio to values 
that suppress the activation of c-Myc, thus contributing to the 
impairment of the G
1
/S transition. This mechanism reinforces 
the cytotoxic activity of pyruvate. The essential feature of this 
model lies on a poor mitochondrial cellular equipment, whose 
saturation by glycolytic reducing equivalents is prevented by the 
aerobic pyruvate conversion to lactate. This effect is produced in 
normal embryonic stem cells and in highly anaplastic tumors, 
while it is not produced in differentiated cells, which are normally 
endowed with an expanded mitochondrial apparatus.
As regards the hypothetical use of these physiological agents 
in anticancer therapy, it should be recalled that their cytotoxicity 
is only operative in the presence of a poor mitochondrial 
apparatus, typical of hypoxia-adapted embryonic stem cells. This 
might, per se, represent a substantial advantage with respect to 
the current chemo- and radiotherapies, which are ineffective 
on this compartment. It must be conceded immediately that 
there is a possible limit to this approach, deriving from the 
fact that the cytotoxicity of these factors might produce a 
negative effect on normal stem cells endowed with a scanty 
mitochondrial equipment, such as adult, hematopoietic stem 
cells.18-23 Nevertheless, our own preliminary experiments showed 
that the sensitivity of these cell types is at least 4 times lower 
than that displayed by the malignant cancer populations tested 
so far, and this would provide a reasonable therapeutic index. 
In addition, the memorization of the mechanism mediating the 
cytotoxicity might allow the accumulation of this effect in the 
target embryonic cancer stem cells through a repetitive drug 
supply, obviating the exhaustive metabolization operated by 
adult tissues.
Materials and Methods
Tumor transplantation and cell transfer in culture
AH130 ascites hepatoma was obtained by T Yoshida24 by 
treating Wistar rats with the carcinogen o-aminoazotoluene. 
After serial transplantations in the rat peritoneal cavity, the tumor 
became composed of isolated spheroidal cells, fed by the ascites 
fluid exuded from the peritoneal vessels. These cells displayed 
a totally undifferentiated phenotype, with a high nucleus/
cytoplasm ratio, few mitochondria, and unlimited self-renewal. 
Maintaining the tumor in vivo, treatments in vitro, and the 
standard procedure for labeling DNA were performed essentially 
as previously described.2,5
Measurement of oxygen consumption
Oxygen consumption (ΔQO
2
) of ascites cells was measured, 
as reported by Del Monte11 by Warburg direct method.25
HPLC measurements
The organic extracts were obtained from AH130 cells 





 at pH 7.4.26 The extracts were completely dehydrated and 
suspended in 20 µl of A running buffer (see below). The HPLC 
apparatus consisted of a Perkin Elmer Series 200 binary pump 
system, equipped with a UV/VIS detector. Data were acquired 
and analyzed by a PC using the Total Chrom Workstation. The 
separation of purines, pyrimidines, NAD, NADH, NADP, and 
NADPH was performed using a Gemini-NX 5-µm particle 
size C18 110A, 250 × 4.60-mm column (Phenomenex), which 
was provided with its own guard column (Guard Cartridge 
System). Freshly prepared standard mixtures (Sigma Aldrich), 
with known concentrations were assayed by ion-pairing HPLC 
for the separation of adenine, guanine, thymine, cytosine, 
uracil, NAD, NADH, NADP, and NADPH, and they were 
detected at a wavelength of 260 nm. The mobile phase was 




 10 mM, methanol 0.125%, 
tetrabutylammonium hydroxide 12 mM) obtained as a 55% 





100 mM, methanol 30%, Sigma-Aldrich), tetrabutylammonium 
hydroxide 2.8 mM. All bases were detected with an isocratic run 
with A buffer in 10 min, whereas NAD, NADH, NADP, and 
NADPH were detected with a step gradient from 100% A to 
95% B in 40 min: both runs were performed at the flow rate 
of 1.2 ml/min. The volume of sample injected was, in all cases, 
20 µl.
K562 cell line
Thirty × 103 K562 cells/ml were plated in RPMI-1640 medium 
supplemented with 10% fetal bovine serum, 50 U penicillin, 
and 50 μg streptomycin/ml (EuroClone).8,9 Incubation was 
performed at 37 °C in a 95% air, 5% CO
2
 atmosphere in a 
humidified incubator.27 Bone marrow cells and lymphocytes 
were obtained and treated as previously described.28,29
Human melanoma cells, tumor spheres, and in vitro self-
renewal assay
Human melanoma cells A375 were from ATCC, whereas 
patient-derived SSM2c and M26c were obtained after approved 
protocol by the Ethic Committee as already described.15 
For adherent culture, cells were grown in DMEM with fetal 
bovine serum (FBS). For melanoma sphere culture, cells were 
seeded at a concentration of 5 cells/µl in DMEM-F12 serum-
free medium with N
2
 supplement, insulin (20 µg/ml), EGF 
(10 ng/ml), FGF-2 (10 ng/ml) (all from Invitrogen), or in 
human embryonic stem cell medium (hESCM), as previously 
described.14 Treatments with PBS or physiological agents 
(pyruvate, folate, thetrahydrofolate) and MTX were performed 
for 5 d in DMEM/F12 or hESCM medium, lowering EGF 
and bFGF concentration to 2 ng/ml. After treatment, spheres 
were dissociated, counted, and plated for self-renewal assay (in 
96-well plates at one cell per well or in 12-well plates at one 
cell per microliter) without the drugs. After 1 wk, spheres were 
counted. All the experiments were performed in triplicate and 
were repeated at least 3 times.
Immunofluorescence
Immunofluorescence for cells in suspension (cytocentrifuged 
at 800 rpm for 15 min at 4 °C) was done essentially as previously 
described in Marzi et al.2 Cell cultures were fixed in 3.7% 
formaldehyde in PBS for 20 min at 4 °C and then incubated with 
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Hoechst at room temperature for 10 min to stain cell nuclei. A375 
cell population was tested for rabbit anti-cleaved caspase3, 1:200 
(Cell Signaling Technology Boston). After washing with PBST, 
the cell cultures were incubated with secondary antibody, anti-
rabbit Cy3 conjugated (Chemicon) (1:800 dilution in PBST/3% 
BSA) for 1 h at room temperature.
Xenografts
In vivo experiments were conducted in accordance with 
National Guidelines and approved by Ethical Committee of 
Animal Welfare Office of Italian Health Ministry. A375 spheres 
treated with PBS or 20 mM pyruvate for 7 d were dissociated, 
resuspended in PBS, and mixed with DMEM/Matrigel in a 1:1 
ratio, and inoculated subcutaneously in adult female athymic 
nude mouse (Foxn1 nu/nu) (1000 cells/injection). Animals were 
monitored daily, subcutaneous tumor size was measured every 
2–3 d by a caliper, and tumor volumes were calculated using the 
formula V = W2 × L × 0.5, where W and L are tumor width 
and length, respectively.15 Mice were euthanized 32 d after 
implantation. For histological analysis, xenografts were fixed in 
4% formaldehyde, paraffin-embedded, cut to 5-μm sections, 
and stained with hematoxylin and eosin (H&E).
Drugs and chemicals
All the substances tested were purchased from Sigma Aldrich 
and added at time 0 at the concentration indicated in the 
legends.
Statistical analysis
Significance levels were calculated with a Student t test: 
*P < 0.05; **P < 0.02; ***P < 0.005.
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